@article{oai:niigata-u.repo.nii.ac.jp:00006419, author = {Kikuchi, Akira}, issue = {4}, journal = {Acta medica et biologica, Acta medica et biologica}, month = {Dec}, note = {We evaluated the antitumor effectiveness of a novel sulfonamide, N-[2-[(4-hydroxyphenyl) amino]-3-pyridinyl] -4-methoxybenzenesulfonamide (E7010), against 10 human ovarian cancer cell lines in vitro. The 50% inhibitory concentrations of E7010 for these cell lines ranged from 0.032 μg/ml to 0.48 μg/ml. Those of cisplatin (CDDP) ranged from 0.021 μg/ml to 1.0 μg/ml. No CDDP-resistant cell lines used in this study showed cross-resistance to E7010. In mice inoculated with Nakajima and KF cells, administration of E7010 in doses of 200-450 mg/kg every 5 days inhibited tumor growth by 11-79%. Moreover, the E7010-treated mice showed less body weight loss than the CDDP-treated mice at doses exerting equal antitumor effects.}, pages = {193--197}, title = {Antitumor Effects of a Novel Sulfonamide, E7010, on Human Ovarian Cancer Cell Lines in Vitro and in Vivo}, volume = {44}, year = {1996} }